Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 790 | 93 | 695 |
| Samples | 248 | 31 | 215 |
| Peptides | 163 | 29 | 137 |
Function
FCGR3A · Fc gamma receptor IIIa
This gene encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other responses, including antibody dependent cellular mediated cytotoxicity and antibody dependent enhancement of virus infections. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene are associated with immunodeficiency 20, and have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2020].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 163 amino-acid changes on canonical ENST00000443193 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FCGR3A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FCGR3A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Rhabdomyosarcoma | 0/33 0% | 6/171 4% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 12/612 2% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 19/1390 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 9/810 1% |
| Melanoma | 2/210 1% | 22/1899 1% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 24/2534 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Colorectal Carcinoma | 5/143 4% | 21/3239 1% |
| Cervical Carcinoma | 1/35 3% | 2/422 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Other Solid Cancers | 0/94 0% | 10/1515 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 9/1592 1% |
| Head and Neck Carcinoma | 0/85 0% | 9/1574 1% |
| Other Blood Cancers | 0/61 0% | 11/2725 0% |
| Gastric Carcinoma | 1/74 1% | 6/1809 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 8/2550 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| Breast Carcinoma | 1/144 1% | 6/3264 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Glioma | 0/52 0% | 3/2127 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
Mutation Distribution
Where FCGR3A is mutated · all tissues, split by cell line vs tissue
How many mutations in FCGR3A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 790 mutations in FCGR3A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|